Sponsors (17)
The bill increases life‑saving naloxone access and training at federal and private worksites but relies on voluntary guidance for many employers, creating potential gaps in coverage while imposing modest costs and an accelerated rulemaking timeline.
Employees and bystanders in both private and federal workplaces (including VA facilities) will have greater access to naloxone and related training, increasing the chances of reversing opioid overdoses on site.
Federal employees and veterans will benefit from standardized OSHA requirements that create consistent, nationwide expectations for naloxone availability and training at federal worksites (including the VA).
Workers and potential bystanders are more likely to be prepared to respond to overdoses because employers are advised to offer voluntary annual training on naloxone use.
Because the employer guidance is voluntary, many private workplaces may not adopt naloxone preparedness measures, leaving large numbers of employees unprotected.
Small businesses and federal agencies will incur costs to purchase, store, replenish naloxone and provide training, which could strain small employers and raise taxpayer-funded operating expenses.
The 270-day deadline for OSHA rulemaking is accelerated and may limit stakeholder input or careful implementation, increasing the risk of uneven rollout or legal challenges.
Based on analysis of 3 sections of legislative text.
OSHA must issue employer guidance and must require every federal agency to keep opioid overdose reversal medication on hand and offer voluntary annual training within 270 days.
Official title: To require the Secretary of Labor to issue guidance and regulations regarding opioid overdose reversal medication and employee training.
Introduced February 10, 2026 by Bonnie Watson Coleman · Last progress February 10, 2026
Requires OSHA to publish non‑mandatory employer guidance on acquiring and maintaining opioid overdose reversal medication and offering voluntary annual employee training within 270 days of enactment. It also requires OSHA to issue regulations within 270 days that mandate every federal agency to acquire and maintain overdose reversal medication and offer voluntary annual training to employees, explicitly including the Veterans Health Administration. The law sets timelines for guidance and regulations, defines "employer" by reference to the OSH Act (while excluding the U.S. Postal Service), and focuses on making naloxone (or equivalent opioid reversal medication) available in workplaces and federal facilities and offering voluntary training on its use.